Abstract Number: 446 • 2017 ACR/ARHP Annual Meeting
Methotrexate Use and Fatigue in Rheumatoid Arthritis Patients: Results from a National Patient Registry
Background/Purpose: Methotrexate (MTX), a synthetic disease-modifying antirheumatic drug (DMARD), is the most commonly used medication for rheumatoid arthritis (RA). Considerable variations between patients taking MTX…Abstract Number: 447 • 2017 ACR/ARHP Annual Meeting
Tocilizumab Had Acceptable Retention Rate in Both Randomized Controlled Trials and Observational Studies: Systematic Review of Rheumatoid Arthritis
Background/Purpose: In general, retention rate in biological DMARDs represent both efficacy and safety. Tocilizumab (TOC) is a humanized monoclonal antibody that binds to the interleukin-6…Abstract Number: 448 • 2017 ACR/ARHP Annual Meeting
Predicting Remission at 6 Months in Early Rheumatoid Arthritis Treated with Conventional Synthetic Dmards
Background/Purpose: Initial treatment of RA with triple csDMARD therapy can achieve remission in a proportion of patients. Others respond poorly yet must wait at least…Abstract Number: 449 • 2017 ACR/ARHP Annual Meeting
Medical Bugs for Pain Relief in Patients with Rheumatoid Arthritis, a Systematic Review
Background/Purpose: Medical bugs, a term used to describe insects and arthropods for medical treatment, have been widely used in the past centuries for pain relief.…Abstract Number: 450 • 2017 ACR/ARHP Annual Meeting
Disease Duration and Withdrawal of Biologic Agents Predict Radiological Progression in a Cohort of Rheumatoid Arthritis Patients in Latin America. a Real World Study
Background/Purpose: Optimal management of Rheumatoid Arthritis (RA) based in identification of patients with risk factors for Joint Damage (JD) progression, is a main strategy, but…Abstract Number: 451 • 2017 ACR/ARHP Annual Meeting
A Matrix Risk Model for Prediction of Radiographic Progression in Early Rheumatoid Arthritis Based on Treatment Response at 3 Months
Background/Purpose: The present study aimed to develop a matix to predict risk of radiographic progression in patients with early rheumatoid arthritis. The focus of this…Abstract Number: 452 • 2017 ACR/ARHP Annual Meeting
Time to First Treatment Is Associated with a Refractory Course of Rheumatoid Arthritis
Background/Purpose: It is an ongoing matter of research, whether the course of rheumatoid arthritis (RA) can be altered by an early intervention, a concept historically…Abstract Number: 453 • 2017 ACR/ARHP Annual Meeting
The Therapy with Tocilizumab Is Not Associated with Periarticular Demineralisation and Finger Joint Space Narrowing in Rheumatoid Arthritis
Background/Purpose: Digital X-ray Radiogrammetry (DXR) and Computer-Aided Joint Space Analysis (CAJSA) are established computer based techniques for the quantification of metacarpal bone mineral density and…Abstract Number: 454 • 2017 ACR/ARHP Annual Meeting
Soluble Urokinase Plasminogen Activator Receptor (suPAR) Correlates with Disease Activity in Early Rheumatoid Arthritis and Reflects Joint Damage over Time
Background/Purpose: The urokinase plasminogen activator receptor (uPAR) is expressed on various cell types and plays important roles in proteolysis, migration and adhesion. Receptor shedding yields…Abstract Number: 455 • 2017 ACR/ARHP Annual Meeting
Analysis of Real-World Treatment Patterns in a Matched Sample of Rheumatology Patients with Continuous Infliximab Therapy or Switched to Biosimilar Infliximab
Background/Purpose: Biosimilar infliximab (CT-P13) was first approved in Europe in 2013.This study compared treatment (tx) patterns of Turkish pts with a diagnosis of rheumatoid arthritis(RA)…Abstract Number: 456 • 2017 ACR/ARHP Annual Meeting
Time from First Symptom Onset to First Advanced Therapy Amongst RA Patients in Latin America
Background/Purpose: To understand the RA patient pathway in Latin America from first symptom onset; including time to diagnosis and to first advanced treatment. Methods: Data…Abstract Number: 457 • 2017 ACR/ARHP Annual Meeting
Levels of Satisfaction with RA Treatment and Associated Alignment between Rheumatologists and Their Patients across Latin America
Background/Purpose: To assess levels of rheumatologist and patient satisfaction with RA treatment across Latin America and any disconnects that may exist between the two in…Abstract Number: 458 • 2017 ACR/ARHP Annual Meeting
Improving Knowledge of Rheumatoid Arthritis Clinical Trial Results Among Rheumatologists: Effect of an Online Educational Intervention
Background/Purpose: While major medical conferences provide the most up-to-date evidence regarding diseases and treatments, time demands and financial constraints are often cited as reasons for…Abstract Number: 459 • 2017 ACR/ARHP Annual Meeting
Disease Course in Seronegative RA Patients Classified According to the 2010 ACR/EULAR Criteria
Background/Purpose: The development of the 2010 classification criteria for rheumatoid arthritis (RA) has led to a redefinition of the patient population, including classification of seropositive…Abstract Number: 460 • 2017 ACR/ARHP Annual Meeting
Usefullness of Serum Angiogenic and Proinflammatory Cytokines to Discriminate between 6 Sets of Remission Criteria and Biomarkers of Radiographic Progression and Clinical Flare in RA in Clinical Remission. Pre-Eliminary Results of a Study of 5 Years of Follow-up
Background/Purpose: The primary aim of this study was to analyse serum levels differences of angiogenic and inflammatory biomarkers between SDAI, CDAI, ACR, DAS28 and sonographic…
ACR Meeting Abstracts